TOP TEN perturbations for 39416_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39416_at
Selected probe(set): 209154_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39416_at (209154_at) across 6674 perturbations tested by GENEVESTIGATOR:
F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-3.7263107Number of Samples:4 / 6
| Experimental | F. tularensis study 1 (tularensis Schu S4) |
| Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours. | |
| Control | uninfected peripheral blood monocyte sample |
| Peripheral blood monocytes uninfected. |
F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-2.7580023Number of Samples:4 / 6
| Experimental | F. tularensis study 1 (novicida) |
| Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours. | |
| Control | uninfected peripheral blood monocyte sample |
| Peripheral blood monocytes uninfected. |
hepatocyte (ESC) / Hep-G2
Relative Expression (log2-ratio):2.6339102Number of Samples:8 / 9
| Experimental | hepatocyte (ESC) |
| Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
| Control | Hep-G2 |
| Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: |
expO lung cancer study 1 (neuroendocrine carcinoma; primary) / expO lung cancer study 1 (adenosquamous carcinoma; primary)
Relative Expression (log2-ratio):-2.5706806Number of Samples:6 / 3
| Experimental | expO lung cancer study 1 (neuroendocrine carcinoma; primary) |
| Primary tumor tissue samples obtained from the lung of patients with neuroendocrine carcinoma. | |
| Control | expO lung cancer study 1 (adenosquamous carcinoma; primary) |
| Primary tumor tissue samples obtained from the lung of patients with adenosquamous carcinoma. |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-2.5031004Number of Samples:3 / 3
| Experimental | oncolytic herpes simplex virus study 2 |
| Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
| Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
| Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
colorectal adenoma study 2 / normal colon tissue
Relative Expression (log2-ratio):-2.4834213Number of Samples:5 / 6
| Experimental | colorectal adenoma study 2 |
| Laser microdissected human adenoma sample. | |
| Control | normal colon tissue |
| Laser microdissected human colonic epithelial cells sample. |
valproic acid study 25 (5000uM) / vehicle (medium) treated hepatocyte sample
Relative Expression (log2-ratio):-2.4056225Number of Samples:2 / 2
| Experimental | valproic acid study 25 (5000uM) |
| Hepatocytes treated with compound: valproic acid (5000uM; CHEMBL109) for 24 hours. ATC code: | |
| Control | vehicle (medium) treated hepatocyte sample |
| Hepatocytes treated with vehicle (medium) for 24 hours. |
expO lung cancer study 1 (neuroendocrine carcinoma; primary) / expO lung cancer study 1 (mucinous adenocarcinoma; primary)
Relative Expression (log2-ratio):-2.362979Number of Samples:6 / 4
| Experimental | expO lung cancer study 1 (neuroendocrine carcinoma; primary) |
| Primary tumor tissue samples obtained from the lung of patients with neuroendocrine carcinoma. | |
| Control | expO lung cancer study 1 (mucinous adenocarcinoma; primary) |
| Primary tumor tissue samples obtained from the lung of patients with mucinous adenocarcinoma. |
expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)
Relative Expression (log2-ratio):2.33319Number of Samples:22 / 4
| Experimental | expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with papillary adenocarcinoma (NOS). | |
| Control | expO kidney cancer study 1 (granular cell carcinoma; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. |
Alzheimer's disease study 8 / normal pyramidal neuron (middle temporal gyrus)
Relative Expression (log2-ratio):2.2734785Number of Samples:15 / 12
| Experimental | Alzheimer's disease study 8 |
| Cortical layer III pyramidal neurons of the middle temporal gyrus of clinically and neuropathologically classified late-onset Alzheimer´s disease afflicted individuals. Subjects in this group had a Braak stage of V or VI with a CERAD score of moderate or frequent. | |
| Control | normal pyramidal neuron (middle temporal gyrus) |
| Cortical layer III pyramidal neurons of the middle temporal gyrus of clinically classified as neurologically normal individuals. Subjects in this group had a Braak stage ranging from I to II with a infrequent Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque density. |
Organism: Homo sapiens
Gene: 39416_at
Selected probe(set): 209154_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39416_at (209154_at) across 6674 perturbations tested by GENEVESTIGATOR:
F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-3.7263107Number of Samples:4 / 6
| Experimental | F. tularensis study 1 (tularensis Schu S4) |
| Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours. | |
| Control | uninfected peripheral blood monocyte sample |
| Peripheral blood monocytes uninfected. |
F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-2.7580023Number of Samples:4 / 6
| Experimental | F. tularensis study 1 (novicida) |
| Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours. | |
| Control | uninfected peripheral blood monocyte sample |
| Peripheral blood monocytes uninfected. |
hepatocyte (ESC) / Hep-G2
Relative Expression (log2-ratio):2.6339102Number of Samples:8 / 9
| Experimental | hepatocyte (ESC) |
| Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
| Control | Hep-G2 |
| Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: |
expO lung cancer study 1 (neuroendocrine carcinoma; primary) / expO lung cancer study 1 (adenosquamous carcinoma; primary)
Relative Expression (log2-ratio):-2.5706806Number of Samples:6 / 3
| Experimental | expO lung cancer study 1 (neuroendocrine carcinoma; primary) |
| Primary tumor tissue samples obtained from the lung of patients with neuroendocrine carcinoma. | |
| Control | expO lung cancer study 1 (adenosquamous carcinoma; primary) |
| Primary tumor tissue samples obtained from the lung of patients with adenosquamous carcinoma. |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-2.5031004Number of Samples:3 / 3
| Experimental | oncolytic herpes simplex virus study 2 |
| Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
| Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
| Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
colorectal adenoma study 2 / normal colon tissue
Relative Expression (log2-ratio):-2.4834213Number of Samples:5 / 6
| Experimental | colorectal adenoma study 2 |
| Laser microdissected human adenoma sample. | |
| Control | normal colon tissue |
| Laser microdissected human colonic epithelial cells sample. |
valproic acid study 25 (5000uM) / vehicle (medium) treated hepatocyte sample
Relative Expression (log2-ratio):-2.4056225Number of Samples:2 / 2
| Experimental | valproic acid study 25 (5000uM) |
| Hepatocytes treated with compound: valproic acid (5000uM; CHEMBL109) for 24 hours. ATC code: | |
| Control | vehicle (medium) treated hepatocyte sample |
| Hepatocytes treated with vehicle (medium) for 24 hours. |
expO lung cancer study 1 (neuroendocrine carcinoma; primary) / expO lung cancer study 1 (mucinous adenocarcinoma; primary)
Relative Expression (log2-ratio):-2.362979Number of Samples:6 / 4
| Experimental | expO lung cancer study 1 (neuroendocrine carcinoma; primary) |
| Primary tumor tissue samples obtained from the lung of patients with neuroendocrine carcinoma. | |
| Control | expO lung cancer study 1 (mucinous adenocarcinoma; primary) |
| Primary tumor tissue samples obtained from the lung of patients with mucinous adenocarcinoma. |
expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)
Relative Expression (log2-ratio):2.33319Number of Samples:22 / 4
| Experimental | expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with papillary adenocarcinoma (NOS). | |
| Control | expO kidney cancer study 1 (granular cell carcinoma; primary) |
| Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. |
Alzheimer's disease study 8 / normal pyramidal neuron (middle temporal gyrus)
Relative Expression (log2-ratio):2.2734785Number of Samples:15 / 12
| Experimental | Alzheimer's disease study 8 |
| Cortical layer III pyramidal neurons of the middle temporal gyrus of clinically and neuropathologically classified late-onset Alzheimer´s disease afflicted individuals. Subjects in this group had a Braak stage of V or VI with a CERAD score of moderate or frequent. | |
| Control | normal pyramidal neuron (middle temporal gyrus) |
| Cortical layer III pyramidal neurons of the middle temporal gyrus of clinically classified as neurologically normal individuals. Subjects in this group had a Braak stage ranging from I to II with a infrequent Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque density. |